Headquartered in Lewisville, TX Fiscal year ends December NYSE: ENOV enovis.com
Enovis Corporation (NYSE: ENOV) is a global medical technology company that develops clinically differentiated orthopedic solutions intended to improve patient outcomes and restore motion.
It operates two segments:
- **Prevention & Recovery (P&R):** U.S. bracing and support products, other U.S. P&R products, and international P&R. The company divested its Dr. Comfort Footcare Solutions product line in October 2025.
- **Reconstructive (Recon):** orthopedic implant and joint reconstruction products sold in the U.S. and internationally, expanded through the acquisition of Lima, which is being integrated under the Enovis brand.
The company sells to surgeons, clinicians and healthcare providers worldwide. It is investing in enabling technologies, including its ARVIS Augmented Reality System and a pending acquisition of eCential Robotics' surgical robotics platform. Its former fabrication technology business was separated and is reported in discontinued operations. Updated
Organic sales rose 5% once the Dr. Comfort divestiture headwind is stripped out, well above the 1.8% reported revenue growth. Management raised full-year adjusted EPS guidance to $3.58 to $3.79 and authorized a new $200 million buyback against a $1.4 billion market cap.
Enovis Corporation (NYSE: ENOV) is a global medical technology company that develops clinically differentiated orthopedic solutions intended to improve patient outcomes and restore motion. It operates two segments: - **Prevention & Recovery (P&R):** U.S. bracing and support products, other U.S.
24/7 Wall St.'s 12-month price target for ENOV is $33.80, rated Buy. The Wall Street consensus target is $36.08. ENOV price prediction →